Back to School: How biopharma can reboot drug development. Access exclusive analysis here

GI-5005: Additional Phase IIb data

Additional data from a Phase IIb trial in 140 patients with chronic HCV genotype 1 showed that significantly more patients receiving GI-5005 plus standard

Read the full 241 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE